🔎 Trials Near Me

Dachaigh › Leukemia Lymphocytic Cronach › Maryland

Sgrùdaidhean clionaigeach Leukemia Lymphocytic Cronach ann an Maryland

Tha 23 sgrùdaidhean airson Leukemia Lymphocytic Cronach a’ lorg phàirtichean aig làraichean ann an Maryland.

Bailtean ann an Maryland

Teacsa sgrùdaidh oifigeil (Beurla)

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • American Oncology Partners of Maryland Pa, Bethesda
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05006716

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

  • Center for Cancer and Blood Disorders ( Site 5439), Bethesda
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05947851

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

  • National Institutes of Health Clinical Center, Bethesda
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 110 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05724121

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Mercy Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
  • agus 10 a bharrachd
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 75 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT05334069

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • GC2202 Study Site 111, Bethesda
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT05645107

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 30 Sult 2026 · NCT04269902

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

  • American Oncology Partners of Maryland Pa, Bethesda
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT06846671

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

  • The University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT06943872

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

  • National Institutes of Health Clinical Center, Bethesda
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 110 · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT00923507

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

  • National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 2
Aoisean 18 gu 85 · Gach gnè · Air ùrachadh 24 Sult 2026 · NCT03986034

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

  • National Institutes of Health Clinical Center, Bethesda
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT01087333

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Johns Hopkins Asthma & Allergy Center, Baltimore
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 21 Sult 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • Maryland Oncology Hematology, Silver Spring
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT07221500

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Maryland, Baltimore
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 8 Sult 2026 · NCT03666000

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

  • National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1 tràth
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 21 Lùna 2026 · NCT07428707

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • American Oncology Partners of Maryland, PA, Bethesda
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Lùna 2026 · NCT05254743

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

  • The Center for Cancer and Blood Disorders-Bethesda, Bethesda
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Lùna 2026 · NCT07342478

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

  • National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1/2
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 16 Iuch 2026 · NCT06364423

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • National Institute of Health, Bethesda
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Iuch 2026 · NCT05131022

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  • American Oncology Partners, PA, Bethesda
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 19 Cèit 2026 · NCT06588478

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

  • Center for Cancer and Blood Disorders-American Oncology Partners of Maryland /ID# 266445, Bethesda
  • Maryland Oncology Hematology - Silver Spring /ID# 267557, Silver Spring
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 9 Gibl 2026 · NCT06428019

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  • National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Màrt 2026 · NCT04830137

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  • University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Dùbh 2025 · NCT05602363

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.